Supplemental material
Journal of Medical Economics
Volume 25, 2022 - Issue 1
Open access
2,314
Views
1
CrossRef citations to date
0
Altmetric
Oncology
Comprehensive genomic profiling in advanced/metastatic colorectal cancer: number needed to test and budget impact of expanded first line use
David Proudmana Analysis Group, Inc., Menlo Park, CA, USACorrespondence[email protected]
https://orcid.org/0000-0002-2295-3473
Nicholas C. DeVitob Duke Cancer Institute, Durham, NC, USA
, Suzanne Belinsonc Tempus Labs, Inc., Chicago, IL, USA
, Mina Alsaraf Alloc Tempus Labs, Inc., Chicago, IL, USA
, Eric D. Morrisa Analysis Group, Inc., Menlo Park, CA, USA
, James Signorovitchd Analysis Group, Inc., Boston, MA, USA
& Anuj K. Patele Dana-Farber Cancer Institute, Boston, MA, USA
show all
Pages 817-825
|
Received 04 Apr 2022, Accepted 18 May 2022, Published online: 16 Jun 2022
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.